# An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

> **NCT04659174** · PHASE3 · COMPLETED · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 152 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Xanomeline and Trospium Chloride Capsules

## Key facts

- **NCT ID:** NCT04659174
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2023-10-03
- **Final completion:** 2023-10-03
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659174, "An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04659174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*